EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Integrated NONMEM-Based Framework for Ticagrelor Exposure–PRU Modeling and Patient-Level Outcome Prediction Assessment

Songrui Du, Jingcheng Chen, Dongyang Liu, Cheng Cui

Pharmaceuticals · 09.11.2026 · 19 (11) · 1780

DOI: 10.3390/ph19111780 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 09.11.2026. Verfasst von Songrui Du und 3 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Research Ward Excellence Program.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Ticagrelor reduces ischemic events in acute coronary syndrome (ACS) but may increase bleeding in susceptible patients. We used a population PK and PK/PD model to describe ticagrelor exposure and platelet reactivity unit (PRU) dynamics and assessed whether model-predicted PRU improved prediction of subsequent outcomes in a patient-level analysis.

Methods

We collated published evidence from 39 ticagrelor clinical studies (172 group-level datasets). The final population PK and indirect-response PK/PD models for ticagrelor, AR-C124910XX, and PRU were implemented in NONMEM with a two-compartment structure, three transit absorption compartments, and prespecified covariate relationships. Model-predicted PRU from recorded prescription exposure was linked to subsequent outcomes in a de-identified UK Biobank cohort using a prespecified 90-day landmark analysis. Cox models with clinical variables, recorded medication exposure, and model-predicted PRU were compared; a 30-day landmark analysis was used for sensitivity analysis.

Results

The final model retained a two-compartment structure with three transit absorption compartments and quantified age, disease status, concomitant aspirin, and fasting effects on exposure. The indirect-response model linked combined parent-metabolite molar concentration to continuous PRU dynamics. In 731 UK Biobank participants, the 90-day ischemic, bleeding, and all-cause death analyses included 112, 48, and 129 events, respectively. Adding model-predicted PRU did not show stable incremental discrimination; all paired-bootstrap intervals for C-index and Brier-score increments crossed zero.

Conclusions

We established a NONMEM-based framework linking ticagrelor dosing, exposure, and PRU dynamics to patient-level outcome prediction assessment. Although incremental predictive benefit was not established in the current cohort, the framework provides a basis for further evaluation using paired measured PK, PRU, and clinical outcome data before clinical application.

Förderung

  • Beijing Research Ward Excellence Program

Zitieren

APA

Du, S., Chen, J., Liu, D., & Cui, C. (2026). An Integrated NONMEM-Based Framework for Ticagrelor Exposure–PRU Modeling and Patient-Level Outcome Prediction Assessment. Pharmaceuticals, 19(11), 1780. https://doi.org/10.3390/ph19111780

Vancouver

Du S, Chen J, Liu D, Cui C. An Integrated NONMEM-Based Framework for Ticagrelor Exposure–PRU Modeling and Patient-Level Outcome Prediction Assessment. Pharmaceuticals. 2026;19(11):1780. doi:10.3390/ph19111780

BibTeX
@article{Du2026,
  author = {Du, Songrui and Chen, Jingcheng and Liu, Dongyang and Cui, Cheng},
  title = {An Integrated NONMEM-Based Framework for Ticagrelor Exposure–PRU Modeling and Patient-Level Outcome Prediction Assessment},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1780},
  doi = {10.3390/ph19111780}
}
Kostenlos starten →